On this page
Quick Reference
Overview and Recommendations
Management
- •Set management goals around reducing PEM, preserving sustainable function, maintaining nutrition and hydration, treating comorbidities, and supporting participation. No curative treatment has been established.
- •Use individualized energy management. Match physical, cognitive, emotional, social, orthostatic, and sensory demands to the current energy envelope, which may contract during infection, poor sleep, pain flares, stress, or relapse.
- •Plan below the level that reliably triggers PEM. Break tasks into smaller components, alternate demanding and low-demand activities, perform tasks seated or recumbent when possible, delegate nonessential work, and schedule rest before predictable exertion.
- •Avoid the boom-and-bust cycle. During a flare, reduce activity to currently tolerated levels, prioritize eating, drinking, toileting, hygiene, medicines, and essential communication, and resume other activities only after symptoms stabilize.
- •Do not prescribe fixed or quota-based incremental exercise or as treatment. advises remaining within the individual energy limit and adjusting the plan during relapse; a 2023 methodological critique challenged aspects of this position, but forced progression through PEM should be avoided.
- •Use physiotherapy or occupational therapy only when individualized, reversible, and symptom-contingent. Focus on safer task performance, positioning, transfers, mobility aids, and participation rather than an exercise quota or a target number of steps.
- •Use shared decision-making and assign a named clinician to coordinate primary care, specialty care, rehabilitation, social care, and carers when the patient consents. Review delayed responses over 24-72 hours after any intervention that increases demand.
- •Support work and education with flexible hours, remote or asynchronous participation, reduced workload, rest breaks, modified deadlines, quiet spaces, and permission to leave early. Judge success by sustainable attendance and delayed symptoms, not performance on a single day.
- •Adapt care for fluctuating or severe illness. Offer remote, home-based, telephone, video, written, or caregiver-assisted review; minimize waiting, bright light, noise, touch, prolonged upright posture, and repeated history-taking.
- •Encourage individualized sleep-wake routines, low-stimulation wind-down periods, and reduction of evening light and screen exposure when tolerated. Investigate suspected sleep apnoea or and offer in a low-burden format when appropriate.
- •Plan meals and fluids around available energy. Use simple, nutrient-dense foods, smaller frequent portions when needed, practical food support, and dietetic assessment for weight loss, dehydration, restricted intake, or malnutrition; do not use restrictive diets or supplements as ME/CFS treatments without a specific indication.
- •For orthostatic symptoms, limit prolonged standing, perform tasks seated or recumbent, rise slowly, use a shower chair when needed, and consider compression or individualized fluid and salt strategies only after assessing contraindications such as hypertension, heart failure, kidney disease, or relevant medication effects.
- •Treat pain according to its phenotype and a defined functional target. A specialist-directed trial may include 5-10 mg orally at bedtime, increased by 5-10 mg every 1-2 weeks only if tolerated, or 100 mg orally at bedtime or 100 mg twice daily, increased by 100-300 mg every 3-7 days according to response and renal function; stop or reduce treatment if sedation, cognitive worsening, falls, orthostatic symptoms, or delayed PEM occurs.
- •Offer only as supportive treatment for coping, grief, insomnia, fear, or illness-related distress; neither CBT nor antidepressant treatment cures ME/CFS. Assess and treat depression, anxiety, trauma-related symptoms, and suicidality independently without attributing PEM or orthostatic intolerance to mood disorder.
- •Provide mobility aids and home adaptations when they reduce orthostatic load, falls, pain, or energy expenditure. In severe or very severe disease, assess nutrition, hydration, swallowing, skin, bowel function, medication administration, transfers, pressure risk, caregiver capacity, and safeguarding with the least stimulating approach possible.
- •Arrange urgent assessment for chest pain, severe or new dyspnoea, hypoxia, cyanosis, syncope with injury, suspected pulmonary embolism, severe dehydration, significant bleeding, airway compromise, acute confusion, new focal neurological deficits, seizure, sudden severe headache, suicidal intent, or rapidly progressive infection. Review persistent fever, sustained weight loss, recurrent vomiting, or marked change from baseline for another or coexisting disorder.
Deep Dive — Evidence Details
What ME/CFS Is: Nomenclature, Core Features, and Case Definitions
- ▸PEM, not fatigue alone, is the defining clinical feature.
- ▸Document the selected case definition and duration threshold.
ME/CFS is a chronic, disabling multisystem illness defined by impaired function, post-exertional malaise (PEM), unrefreshing sleep, and cognitive or autonomic symptoms.[1] PEM is delayed, disproportionate worsening after physical, cognitive, emotional, orthostatic, or sensory activity; recovery may take days or longer.[3] Diagnosis is clinical: no biomarker reliably confirms or excludes it.[10] Fukuda criteria are broad and do not require PEM; and require PEM and multisystem features; 2015 criteria require functional impairment, PEM, unrefreshing sleep, and cognitive impairment or .[1][3][13][20] NICE requires debilitating fatigue, PEM, unrefreshing sleep, and cognitive difficulty for at least 3 months.[2] overlaps but requires preceding COVID-19; it is not synonymous with ME/CFS.[7][8]
Epidemiology, Triggers, and Populations at Risk
- ▸Trigger history is useful, but infection is not required.
- ▸Recorded prevalence reflects recognition and access as well as illness burden.
Prevalence varies by case definition and ascertainment: reported estimates range from 0.4-0.6% to 0.3-0.9%, while 1.5% of US adults reported ever receiving an ME/CFS diagnosis.[21][22][23] Women are diagnosed approximately four times as often as men.[21] Onset distributions show peaks near 16 and 37 years, though registry age at diagnosis may not equal onset.[21] Infection precedes illness in 49% of European survey respondents and 62.4% of DecodeME participants; approximately 10% developed ME/CFS 12 months after infectious mononucleosis in selected cohorts.[21] Surgery, injury, pregnancy, vaccination, and stress are reported triggers but do not establish causation. Post-SARS-CoV-2 cohorts overlap with ME/CFS; post-COVID illness and ME/CFS must not be counted as synonymous.[22][25] Diagnostic delay and socioeconomic inequity are common.[21][26]
Proposed Biological Mechanisms and Disease Models
- ▸Resting tests may miss state-dependent abnormalities.
- ▸Mechanistic findings are research hypotheses, not diagnostic or routine treatment targets.
ME/CFS is best modeled as impaired physiological adaptation across immune, metabolic, vascular, autonomic, sleep, gastrointestinal, and central nervous systems rather than one proven lesion.[34] Postinfectious immune remodeling may affect metabolism, endothelium, and neural function, but candidate cytokines, metabolites, autoantibodies, and imaging findings remain associations.[35] Some two-day CPET studies report reduced second-day oxygen consumption and workload, whereas a 2026 replication found no significant day-to-day changes, so CPET is not a diagnostic test.[34][39] Proposed mechanisms include reduced metabolic flexibility, orthostatic cerebral hypoperfusion, endothelial dysfunction, immune-cell remodeling, altered HPA-axis regulation, microbiome changes, sleep disruption, and central sensory or cognitive processing abnormalities.[40][42][44][46][47-50] No proposed biomarker has adequate specificity or causal proof.[34][52][53]
Clinical Phenotype: PEM and Multisystem Manifestations
- ▸Assess the activity, delay, symptom change, functional loss, and recovery time.
- ▸Cognitive, upright, sensory, and emotional demands can provoke PEM.
PEM is delayed, disproportionate symptom and functional worsening after modest physical, cognitive, emotional, orthostatic, or sensory demand; it may peak within 72 hours and last days or weeks.[54][56] Ordinary fatigue improves with rest and lacks this delayed loss of capacity. Associated features include unrefreshing sleep; cognitive slowing, impaired attention, and word-finding difficulty; with light-headedness, palpitations, presyncope, or cognitive worsening; widespread pain, headache, sensory sensitivity, flu-like symptoms, gastrointestinal and genitourinary complaints, and thermoregulatory disturbance.[16][18][58][59][67] Orthostatic testing identifies POTS or orthostatic hypotension in some patients but is not required. Functional capacity fluctuates over hours to months; a normal clinic examination does not exclude severe disability.
Clinical Diagnosis: History, Examination, and Criteria
- ▸Do not provoke PEM with exercise testing.
- ▸A normal resting examination does not negate delayed exertional disability.
Begin with premorbid versus current function: work or school, walking, bathing, shopping, meals, social contact, upright time, and assistance required.[1] Characterize PEM using a concrete example and ask about delayed worsening at the same day and 24-72 hours. Assess unrefreshing sleep, cognition, orthostatic symptoms, pain, sensory sensitivity, gastrointestinal and genitourinary symptoms, medications, mood, sleep disorders, pregnancy, infection, and other systemic disease.[60] Examine vitals, weight, hydration, heart, lungs, thyroid, lymph nodes, neurological function, gait, joints, and skin. Measure supine and standing pulse and blood pressure when safe; formal autonomic testing is selective.[73] Apply one stated case definition explicitly and document why comorbidities do or do not explain the complete pattern.
Investigations: Excluding Alternative Disease Without Overtesting
- ▸Test to answer a clinical question, not to find an ME/CFS biomarker.
- ▸Repeat testing only after a meaningful clinical change.
Investigations identify treatable alternatives and comorbidities; no test confirms or excludes ME/CFS.[83][86] Initial testing commonly includes CBC, electrolytes, renal and liver tests, calcium, glucose or , , or , ferritin, and . Add B12, folate, vitamin D, creatine kinase, or when indicated; perform pregnancy or infection testing according to risk.[88] Use ECG, echocardiography, rhythm monitoring, polysomnography, MRI, EMG, or formal autonomic testing only for specific symptoms or findings. Do not order commercial cytokine panels, unvalidated metabolomics, remote viral serologies, routine imaging, or exercise challenges to confirm ME/CFS.[92] Reassess new fever, bleeding, weight loss, focal deficits, or organ-specific symptoms.
Differential Diagnosis and Common Comorbidity
- ▸PEM is more discriminating than fatigue severity.
- ▸Coexisting disease does not exclude ME/CFS if it fails to explain the full phenotype.
The competing diagnosis must explain the entire pattern, especially delayed PEM, unrefreshing sleep, cognitive dysfunction, orthostatic symptoms, and multisystem fluctuation.[95][96] Consider anemia, thyroid or adrenal disease, diabetes, inflammatory or autoimmune disease, infection, cardiopulmonary or neurological disease, malignancy, sleep disorders, medication effects, nutritional deficiency, primary psychiatric disorders, deconditioning, burnout, , , POTS, and orthostatic hypotension. Treatable conditions can mimic, trigger, worsen, or coexist with ME/CFS. , migraine, IBS, sleep disorders, POTS, endocrine disease, and depression are common comorbidities.[96] Do not attribute new objective weakness, persistent fever, bleeding, focal neurological signs, sustained weight loss, or organ-specific inflammation to ME/CFS without evaluation.[88][95][101][105]
Severity, Functional Capacity, and Outcome Measurement
- ▸Measure what the patient can sustain repeatedly, not what they can do once.
- ▸Assessment itself must not provoke PEM.
Severity is defined by sustainable function and recovery, not symptom count.[110] Mild illness permits reduced work or education; moderate illness prevents full-time participation and requires frequent rest; severe illness limits activity to basic self-care and often requires assistance; very severe illness may involve bed confinement, communication or sensory intolerance, and continuous care.[110] Document upright tolerance, mobility, cognition, communication, self-care, meals, time out of bed, caregiver support, and good-day/bad-day variation. Use diaries, caregiver accounts, school or employment records, PROMIS, DSQ, fatigue scales, Bell disability scale, and WSAS as adjuncts, not diagnostic tests.[110][111][114] A 2026 replication found no significant day-to-day CPET change, so CPET should not define PEM or disability.[39]
Management Principles: Energy Management, Pacing, and Collaborative Care
- ▸Pacing is symptom-contingent; stop or reduce activity when PEM appears.
- ▸Coordinate primary care, rehabilitation, social care, education, and employment support.
Management aims to reduce PEM, preserve function, support nutrition and hydration, and treat comorbidities; no curative therapy is established.[121] Pacing matches physical, cognitive, emotional, orthostatic, and sensory demands to a changing energy envelope. Break tasks into components, alternate demand and rest, use seated or recumbent methods, delegate, and plan rest before predictable exertion.[120][123] Avoid boom-and-bust cycles. NICE advises remaining within individual energy limits and specifically rejects fixed or quota-based incremental exercise, including (GET), as treatment.[121] Rehabilitation, if used, must be flexible, reversible, and symptom-contingent; increased activity is earned by sustained stability, not prescribed as a target. Provide remote or home reviews, mobility aids, work or school accommodations, and a relapse plan.[121]
Symptom-Directed Treatment
- ▸Judge benefit by sustainable function over 24-72 hours.
- ▸Treat POTS or orthostatic hypotension separately; neither explains PEM alone.
Treat symptoms and comorbidities without implying that ME/CFS is psychiatric; CBT is supportive, not curative.[121][138] Sleep care includes individualized schedules, sensory reduction, evaluation for sleep apnea or restless legs, and low-burden CBT-I.[50][141] Start drugs low and change one at a time. Common specialist pain options include amitriptyline 5-10 mg nightly, increasing by 5-10 mg every 1-2 weeks; duloxetine 20-30 mg daily, then 30-60 mg; or gabapentin 100 mg nightly or twice daily, titrated cautiously.[31] For orthostatic intolerance, use recumbent strategies, compression, and individualized fluids/salt; specialist options include fludrocortisone 0.05-0.1 mg each morning, midodrine 2.5-5 mg two or three times daily while upright, propranolol 5-10 mg once or twice daily, or ivabradine 2.5-5 mg twice daily.[128][129] Monitor PEM, sedation, blood pressure, falls, renal function, electrolytes, and interactions.
Severe and Very Severe ME/CFS
- ▸Preserve the patient’s sustainable baseline rather than testing maximal performance.
- ▸Coordinate nursing, nutrition, occupational therapy, social care, pharmacy, and safeguarding.
Severe disease may leave only eating, toileting, or brief communication possible; very severe disease can require continuous assistance and artificial nutrition.[110][147] Use home-based or remote assessment, short low-stimulation encounters, supine examination, asynchronous communication, and caregiver-supported history. Minimize light, sound, touch, transfers, and waiting; review delayed effects for 72 hours. Monitor hydration, weight, intake, swallowing, bowel function, skin, falls, transfers, medicines, infection, and caregiver capacity. Provide pressure redistribution, individualized repositioning, mobility and transfer aids, dietetic and speech-language assessment, and practical food or fluid access. Severe malnutrition requires cautious refeeding with phosphate, potassium, magnesium, and glucose monitoring because refeeding syndrome can cause arrhythmia, heart failure, delirium, seizures, or death.[147] Emergency evaluation is required for severe dehydration, airway compromise, suspected pulmonary embolism, sepsis, acute neurological deficits, chest pain, hypoxia, or suicidal intent.
ME/CFS Across the Lifespan and Special Contexts
- ▸A good hour or school day does not prove sustainable capacity.
- ▸Use developmentally and communication-appropriate functional measures.
In children and adolescents, assess developmental baseline, school participation, delayed PEM, caregiver observations, and safeguarding. Early onset peaks near 16 years and has been associated with greater odds of severe or very severe illness (OR 2.15, 95% CI 1.84-2.51).[21] Provide flexible attendance, remote access, quiet space, rest, reduced homework, and alternatives to compulsory sport; avoid coercive exercise.[119] During pregnancy and postpartum, reassess orthostasis, nutrition, sleep, medicines, delivery planning, feeding, and practical support; review every drug for pregnancy and lactation safety. In older adults, reassess falls, nutrition, cognition, polypharmacy, malignancy, cardiopulmonary and neurological disease. For disability or limited communication, use accessible communication and personal baselines. , , migraine, POTS, hypermobility, and autoimmune disease may coexist; apply each diagnosis independently.[41][143]
Natural History, Prognosis, Follow-Up, and Research Priorities
- ▸Judge improvement by durable function and recovery, not a transient good day.
- ▸Every meaningful change should trigger review for comorbidity or a new diagnosis.
ME/CFS may improve, remit, relapse, remain stable, or progressively worsen; prognosis varies by cohort, severity, duration, criteria, and access to care. A 2026 protocol summarizes literature suggesting fewer than 10% return to pre-illness functioning without treatment, but this is not an individual prediction.[168] Follow-up should measure PEM threshold, recovery time, sustainable function, sleep, orthostatic symptoms, nutrition, mood, medicines, accommodations, and caregiver strain. Mild or stable patients may be reviewed every 3-6 months; moderate or unstable illness usually requires 4-12-week review; severe illness requires home or remote monitoring based on nutrition, hydration, pressure, falls, and medication risk. New fever, bleeding, weight loss, focal deficits, persistent vomiting, or organ-specific symptoms require reassessment.[169][170] Research priorities are validated biomarkers, harmonized definitions, longitudinal phenotyping, inclusion of severe disease, and trials measuring PEM, sustainable function, harms, and quality of life.[172][174]
References
- [1]
Fan J, Jiao J, Chang HQ et al.. “Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management.” Journal of translational medicine (2025). PMID: 41366804 ↗
Journal Article, ReviewCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions, Clinical Diagnosis: History, Examination, and Application of Criteria, Management Principles: Energy Management, Pacing, and Collaborative Care - [2]
Barry PW, Kelley K, Tan T et al.. “NICE guideline on ME/CFS: robust advice based on a thorough review of the evidence.” Journal of neurology, neurosurgery, and psychiatry (2024). PMID: 38418217 ↗
Journal Article, ReviewCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [3]
Hoffmann K, Hainzl A, Stingl M et al.. “[Interdisciplinary, collaborative D-A-CH (Germany, Austria and Switzerland) consensus statement concerning the diagnostic and treatment of myalgic encephalomyelitis/chronic fatigue syndrome].” Wiener klinische Wochenschrift (2024). PMID: 38743348 ↗
Journal Article, Consensus Statement, English AbstractCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions, Management Principles: Energy Management, Pacing, and Collaborative Care, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [4]
Xu Q, Zhao M, Wang Q et al.. “Chronic fatigue syndrome: From etiology and mechanism to diagnosis and treatment.” Journal of psychiatric research (2026). PMID: 41707618 ↗
Journal Article, Review, Research Support, Non-U.S. Gov'tCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions, Clinical Diagnosis: History, Examination, and Application of Criteria - [5]
Arron HE, Marsh BD, Kell DB et al.. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: the biology of a neglected disease.” Frontiers in immunology (2024). PMID: 38887284 ↗
Journal Article, Review, Research Support, Non-U.S. Gov'tCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions - [6]
van der Meulen ML, Bos M, Bakker SJL et al.. “Validity and diagnostic overlap of functional somatic syndrome diagnoses.” Journal of psychosomatic research (2024). PMID: 38678828 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions, Differential Diagnosis and Conditions That Commonly Coexist - [7]
Dehlia A, Guthridge MA. “The persistence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis.” The Journal of infection (2024). PMID: 39353473 ↗
Journal Article, Meta-Analysis, Systematic ReviewCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions - [8]
Toepfner N, Brinkmann F, Augustin S et al.. “Long COVID in pediatrics-epidemiology, diagnosis, and management.” European journal of pediatrics (2024). PMID: 38279014 ↗
Journal Article, ReviewCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions, Investigations: Excluding Alternative Disease Without Overtesting, Differential Diagnosis and Conditions That Commonly Coexist, Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [9]
Davenport TE, Blitshteyn S, Clague-Baker N et al.. “Long COVID Is Not a Functional Neurologic Disorder.” Journal of personalized medicine (2024). PMID: 39201991 ↗
Journal Article, ReviewCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions - [10]
Clarke KSP, Kingdon CC, Hughes MP et al.. “The search for a blood-based biomarker for Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS): from biochemistry to electrophysiology.” Journal of translational medicine (2025). PMID: 39905423 ↗
Journal Article, ReviewCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions - [11]
Park JW, Park BJ, Lee JS et al.. “Systematic review of fatigue severity in ME/CFS patients: insights from randomized controlled trials.” Journal of translational medicine (2024). PMID: 38831460 ↗
Journal Article, Systematic Review, Meta-Analysis, Research Support, Non-U.S. Gov'tCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions - [12]
Todhunter-Brown A, Campbell P, Broderick C et al.. “Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map.” Health technology assessment (Winchester, England) (2025). PMID: 40162526 ↗
Journal Article, Systematic ReviewCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions, Clinical Diagnosis: History, Examination, and Application of Criteria - [13]
van Campen CLMC, Rowe PC, Visser FC. “Worsening Symptoms Is Associated with Larger Cerebral Blood Flow Abnormalities during Tilt-Testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Medicina (Kaunas, Lithuania) (2023). PMID: 38138257 ↗
Journal ArticleCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions, Investigations: Excluding Alternative Disease Without Overtesting - [14]
Oosterman JM, van der Schaaf M, de Kleijn WPE et al.. “The association of fatigue and pain with cognitive test performance in patients with myalgic encephalomyelitis/chronic fatigue syndrome.” Journal of psychosomatic research (2025). PMID: 41101039 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions - [15]
Huhmar HM, Soinne LS, Bertilson BC et al.. “Low Vasopressin in Myalgic Encephalomyelitise/Chronic Fatigue Syndrome.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025). PMID: 41475665 ↗
Journal Article, Observational StudyCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions - [16]
Mansoubi M, Richards T, Ainsworth-Wells M et al.. “Understanding symptom clusters, diagnosis and healthcare experiences in myalgic encephalomyelitis/chronic fatigue syndrome and long COVID: a cross-sectional survey in the UK.” BMJ open (2025). PMID: 40180399 ↗
Journal ArticleCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions, Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [17]
Weigel B, Eaton-Fitch N, Thapaliya K et al.. “Illness presentation and quality of life in myalgic encephalomyelitis/chronic fatigue syndrome and post COVID-19 condition: a pilot Australian cross-sectional study.” Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2024). PMID: 38961009 ↗
Journal ArticleCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions, Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [18]
Weigel B, Eaton-Fitch N, Thapaliya K et al.. “A pilot cross-sectional investigation of symptom clusters and associations with patient-reported outcomes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post COVID-19 Condition.” Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2024). PMID: 39361124 ↗
Journal ArticleCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions, Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [19]
Berkis U, Svirskis S, Krumina A et al.. “Exploring the joint potential of inflammation, immunity, and receptor-based biomarkers for evaluating ME/CFS progression.” Frontiers in immunology (2023). PMID: 38187396 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions - [20]
Unger ER, Lin JS, Wisk LE et al.. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection.” JAMA network open (2024). PMID: 39046739 ↗
Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov'tCited in: What ME/CFS Is: Nomenclature, Core Features, and Case Definitions - [21]
McGrath SJ, Hillier CB, Dibble JJ et al.. “Incidence age is bimodal for myalgic encephalomyelitis/chronic fatigue syndrome, with higher severity burden for early onset disease.” Oxford open immunology (2026). PMID: 41983041 ↗
Journal ArticleCited in: Epidemiology, Triggers, and Populations at Risk, Severity, Functional Capacity, and Outcome Measurement, Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications, ME/CFS Across the Lifespan and in Special Clinical Contexts - [22]
Tack M, Gruber R, Betting L et al.. “Assessment and Incidence Determination of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Following a SARS-CoV-2 Infection in a Prospective Cohort of Hospital Employees.” Medicina (Kaunas, Lithuania) (2026). PMID: 41901562 ↗
Journal ArticleCited in: Epidemiology, Triggers, and Populations at Risk - [23]
Fleig K, Nahin R, Stussman B et al.. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome diagnostic reporting in the 2021-2023 National Health Interview Survey.” BMC public health (2026). PMID: 42104344 ↗
Journal ArticleCited in: Epidemiology, Triggers, and Populations at Risk, Clinical Diagnosis: History, Examination, and Application of Criteria, ME/CFS Across the Lifespan and in Special Clinical Contexts - [24]
Jason LA, Furst J, Katz BZ. “Comparing ME/CFS following mononucleosis with Long COVID.” Chronic illness (2026). PMID: 41984971 ↗
Journal ArticleCited in: Epidemiology, Triggers, and Populations at Risk, ME/CFS Across the Lifespan and in Special Clinical Contexts - [25]
Sardell JM, Das S, Pearson M et al.. “Identification of novel reproducible combinatorial genetic risk factors for myalgic encephalomyelitis in the DecodeME patient cohort and commonalities with long COVID.” Journal of translational medicine (2026). PMID: 42015188 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Epidemiology, Triggers, and Populations at Risk - [26]
Bowden N, McLeod K, Anns F et al.. “Health, labour market, and social service outcomes for people with Myalgic Encephalomyelitis / Chronic Fatigue Syndrome on a health or disability related benefit: an Aotearoa | New Zealand nationwide cross-sectional study using the integrated data infrastructure.” BMC public health (2026). PMID: 42032509 ↗
Journal ArticleCited in: Epidemiology, Triggers, and Populations at Risk, Severity, Functional Capacity, and Outcome Measurement, ME/CFS Across the Lifespan and in Special Clinical Contexts - [27]
Tomić S, Pastornački A, Drljača M et al.. “Long-Term Follow-Up of Women with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A 16-Year Longitudinal Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356126 ↗
Journal ArticleCited in: Epidemiology, Triggers, and Populations at Risk, Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations, Severity, Functional Capacity, and Outcome Measurement - [28]
Habermann-Horstmeier L, Horstmeier LM. “Sex- and menopause-related differences in immune and gastrointestinal symptom architecture in ME/CFS: evidence from factor analysis and structural equation modeling.” Journal of translational medicine (2026). PMID: 42522006 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Epidemiology, Triggers, and Populations at Risk, Natural History, Prognosis, Follow-Up, and Research Priorities - [29]
Jin H, An Y, Huang J et al.. “Pathophysiological mechanisms of post-exertional malaise: an integrative analysis based on the metabolism-immune-neuro interaction model.” Frontiers in immunology (2026). PMID: 42051540 ↗
Journal Article, Systematic ReviewCited in: Epidemiology, Triggers, and Populations at Risk - [30]
Nematbakhsh S, Mohammadifard N, Riahi R et al.. “Prediction of post-COVID chronic fatigue syndrome using data mining and machine learning techniques in Isfahan COVID cohort study.” Journal of infection and public health (2026). PMID: 42000587 ↗
Journal ArticleCited in: Epidemiology, Triggers, and Populations at Risk - [31]
Grach SL, Seltzer J, Mueller MR et al.. “Underuse of Pharmacologic Therapies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Before Specialist Evaluation.” Annals of family medicine (2026). PMID: 42055743 ↗
Journal ArticleCited in: Epidemiology, Triggers, and Populations at Risk, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity, ME/CFS Across the Lifespan and in Special Clinical Contexts - [32]
Iskander JK, Haridopolos S. “Making Invisible Illnesses Visible: Recognizing and Responding to Infection-Associated Chronic Conditions.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41967005 ↗
Case Reports, Journal Article, Review, Research Support, N.I.H., ExtramuralCited in: Epidemiology, Triggers, and Populations at Risk, ME/CFS Across the Lifespan and in Special Clinical Contexts - [33]
Seltzer J, Grach SL, Eggers SD et al.. “Improving Diagnostic Accuracy of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Through a Point-of-Care Clinical Algorithm.” International journal of environmental research and public health (2026). PMID: 42074399 ↗
Journal ArticleCited in: Epidemiology, Triggers, and Populations at Risk - [34]
Watton P, Prusty BK. “Reframing ME/CFS: toward a unified mechanistic model of chronic post-infectious diseases.” Journal of translational medicine (2026). PMID: 42174604 ↗
Journal Article, ReviewCited in: Proposed Biological Mechanisms and Disease Models, Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [35]
Hu Z, Wang J, Ma S et al.. “Immune remodeling and metabolic reprogramming in chronic fatigue: insights into GPCR signaling and epigenetic regulation.” Frontiers in immunology (2026). PMID: 42220511 ↗
Journal Article, ReviewCited in: Proposed Biological Mechanisms and Disease Models - [36]
Frank J, Nesterovitch N, Movva C et al.. “Toward a Molecular Reclassification of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Integrating Multi-Omics, Machine Learning, and Precision Medicine.” International journal of molecular sciences (2026). PMID: 42196410 ↗
Journal Article, ReviewCited in: Proposed Biological Mechanisms and Disease Models - [37]
Gile B, Bulbule S, Toriola MA et al.. “Association of rapamycin treatment with the modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in ME/CFS subjects: pilot findings from phase-II observational study.” Journal of translational medicine (2026). PMID: 42432754 ↗
Journal Article, Clinical Trial, Phase II, Observational Study, Research Support, N.I.H., ExtramuralCited in: Proposed Biological Mechanisms and Disease Models - [38]
Souma B, Elremaly W, Akoume MY et al.. “Irisin Signaling Resistance in Myalgic Encephalomyelitis: A Proposed Mechanistic Framework for Post-Exertional Malaise Involving the TSP-1-HSP90α-αvβ5 Axis.” International journal of molecular sciences (2026). PMID: 42278300 ↗
Journal ArticleCited in: Proposed Biological Mechanisms and Disease Models - [39]
Mancini DM, Cook DB, Brunjes DL et al.. “Cardiopulmonary exercise test results do not change over two sequential days in patients with chronic fatigue syndrome.” Frontiers in physiology (2026). PMID: 42212259 ↗
Journal ArticleCited in: Proposed Biological Mechanisms and Disease Models, Severity, Functional Capacity, and Outcome Measurement - [40]
Miwa K. “Orthostatic intolerance with small heart and/or disequilibrium in patients with myalgic encephalomyelitis/chronic fatigue syndrome: clinical update and paradigm shift.” Frontiers in medicine (2026). PMID: 42591853 ↗
Journal Article, ReviewCited in: Proposed Biological Mechanisms and Disease Models, Severity, Functional Capacity, and Outcome Measurement, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [41]
Azcue N, Barranco C, Tijero-Merino B et al.. “Two-timepoint multidomain follow-up of post-COVID condition and ME/CFS: overlapping autonomic, small-fiber, and cognitive changes.” Journal of translational medicine (2026). PMID: 42286686 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Proposed Biological Mechanisms and Disease Models, Severity, Functional Capacity, and Outcome Measurement, ME/CFS Across the Lifespan and in Special Clinical Contexts - [42]
Petrov S, Bozhkova M, Ivanovska M et al.. “Comprehensive Immunophenotyping of Monocytes and Dendritic Cells Suggests Distinct Pathophysiology in Chronic Fatigue Syndrome and Long COVID.” International journal of molecular sciences (2026). PMID: 42196466 ↗
Journal ArticleCited in: Proposed Biological Mechanisms and Disease Models - [43]
Aregawi L, Walitt B, Sullivan P et al.. “Central noradrenergic deficiency in post-infectious chronic fatigue: neurobehavioral correlates.” Brain communications (2026). PMID: 42205163 ↗
Journal ArticleCited in: Proposed Biological Mechanisms and Disease Models - [44]
Donchev D, Nikolova R, Vaseva K et al.. “Comparative Gut Microbiome Alterations in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID-19 Syndrome.” Biomedicines (2026). PMID: 42351611 ↗
Journal ArticleCited in: Proposed Biological Mechanisms and Disease Models - [45]
Brown M, Vernon SD, Indart AC et al.. “Gastrointestinal symptoms correlate with core clinical features and systemic inflammation in myalgic encephalomyelitis/chronic fatigue syndrome.” Journal of translational medicine (2026). PMID: 42321833 ↗
Journal Article, Research Support, N.I.H., ExtramuralCited in: Proposed Biological Mechanisms and Disease Models, Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [46]
Wallraven T, Günthner R, Lethen I et al.. “Microvascular remodeling and endothelial dysfunction across the post-COVID-19 spectrum: a prospective observational case-control study.” BMC medicine (2026). PMID: 42625188 ↗
Journal Article, Observational StudyCited in: Proposed Biological Mechanisms and Disease Models, Natural History, Prognosis, Follow-Up, and Research Priorities - [47]
Bedard P, Knutson KM, McGurrin PM et al.. “Central origin of fatigability in Myalgic encephalomyelitis/chronic fatigue syndrome revealed by multimodal neuroimaging.” NeuroImage. Clinical (2026). PMID: 42551185 ↗
Journal ArticleCited in: Proposed Biological Mechanisms and Disease Models - [48]
Singh TB, Marshall-Gradisnik S, Barnden L et al.. “Microstructural alterations in brain tissue of ME/CFS and long COVID using diffusion tensor imaging and diffusion kurtosis imaging.” Frontiers in medicine (2026). PMID: 42539798 ↗
Journal ArticleCited in: Proposed Biological Mechanisms and Disease Models - [49]
Kumar S, Veldhuis A, Yazdani F. “Higher-order brain processes, rather than early processing, underlie sensory problems in ME/CFS: evidence from ERPs.” Frontiers in medicine (2026). PMID: 42396162 ↗
Journal ArticleCited in: Proposed Biological Mechanisms and Disease Models - [50]
Saurel M, Fornasieri I, Del Sordo GC et al.. “Sleep in myalgic encephalomyelitis/chronic fatigue syndrome shows marked night-to-night fluctuation under free-living conditions-results from a matched case-control study.” Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2026). PMID: 42129014 ↗
Journal ArticleCited in: Proposed Biological Mechanisms and Disease Models, Severity, Functional Capacity, and Outcome Measurement, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [51]
Cambras T, Domingo JC, Sanmartín-Sentañes R et al.. “Association between light exposure patterns and multidimensional health outcomes in individuals with myalgic encephalomyelitis/chronic fatigue syndrome: findings from an observational cross-sectional cohort study.” Journal of translational medicine (2026). PMID: 42399727 ↗
Journal Article, Observational Study, Research Support, Non-U.S. Gov'tCited in: Proposed Biological Mechanisms and Disease Models, Severity, Functional Capacity, and Outcome Measurement - [52]
Ikeda G, Koike-Ieki M, Inoue H et al.. “Plasma Extracellular Vesicle Surface Marker Profiling Reveals Immune Cell-Associated Mitochondrial Membrane Potential Alterations in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Open forum infectious diseases (2026). PMID: 42131622 ↗
Journal ArticleCited in: Proposed Biological Mechanisms and Disease Models - [53]
Chinnappan B, Kempuraj D, Aenlle KK et al.. “Elevated serum levels of interleukin-11 and matrix metalloproteinase-9 in myalgic encephalomyelitis/chronic fatigue syndrome.” Frontiers in immunology (2026). PMID: 42327760 ↗
Journal ArticleCited in: Proposed Biological Mechanisms and Disease Models, ME/CFS Across the Lifespan and in Special Clinical Contexts - [54]
Berardi G, Janowski A, McNally S et al.. “Postexertional Symptom Exacerbation after Submaximal Exercise in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Postacute Sequelae of COVID-19.” Medicine and science in sports and exercise (2025). PMID: 41185151 ↗
Journal ArticleCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [55]
Keller B, Receno CN, Franconi CJ et al.. “Cardiopulmonary and metabolic responses during a 2-day CPET in myalgic encephalomyelitis/chronic fatigue syndrome: translating reduced oxygen consumption to impairment status to treatment considerations.” Journal of translational medicine (2024). PMID: 38965566 ↗
Journal Article, Research Support, N.I.H., ExtramuralCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [56]
Baraniuk JN. “Exertional Exhaustion (Post-Exertional Malaise, PEM) Evaluated by the Effects of Exercise on Cerebrospinal Fluid Metabolomics-Lipidomics and Serine Pathway in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” International journal of molecular sciences (2025). PMID: 39941050 ↗
Journal ArticleCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [57]
Moezzi A, Ushenkina A, Widgren A et al.. “Haptoglobin phenotypes and structural variants associate with post-exertional malaise and cognitive dysfunction in myalgic encephalomyelitis.” Journal of translational medicine (2025). PMID: 40877900 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [58]
Sanal-Hayes NEM, Mclaughlin M, Hayes LD et al.. “Examining Well-Being and Cognitive Function in People With Long COVID and ME/CFS, and Age-Matched Healthy Controls: A Case-Case-Control Study.” The American journal of medicine (2024). PMID: 38750713 ↗
Journal ArticleCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [59]
Jason LA, McGarrigle WJ, Vermeulen RCW. “The Head-Up Tilt Table Test as a Measure of Autonomic Functioning among Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of personalized medicine (2024). PMID: 38540980 ↗
Journal ArticleCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [60]
Lu J, Sun W, Li S et al.. “Assessment of symptoms in myalgic encephalomyelitis/chronic fatigue syndrome: a comparative study of existing scales.” Frontiers in neurology (2025). PMID: 41341517 ↗
Journal Article, ReviewCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations, Clinical Diagnosis: History, Examination, and Application of Criteria - [61]
Dudova D, Bozhkova M, Petrov S et al.. “Insights into the Complex Biological Network Underlying Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” International journal of molecular sciences (2025). PMID: 41516145 ↗
Journal Article, ReviewCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [62]
Goldenberg DL. “The pivotal role of central sensitization in long COVID, fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome.” Expert review of neurotherapeutics (2025). PMID: 40512228 ↗
Journal Article, ReviewCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [63]
Nemat-Gorgani M, Jensen MA, Davis RW. “Glymphatic System Dysregulation as a Key Contributor to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” International journal of molecular sciences (2025). PMID: 41373677 ↗
Journal Article, ReviewCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [64]
Poomkudy JT, Torres C, Jason LA et al.. “Joint Flexibility and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After Mononucleosis.” Clinical therapeutics (2024). PMID: 38242746 ↗
Journal ArticleCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [65]
Ghali A, Lavigne C, Ghali M et al.. “Post-Exertional Malaise in Post-COVID-19 Syndrome: A Shift in the Frequency Across Pandemic Phases.” Journal of clinical medicine (2026). PMID: 42074751 ↗
Journal ArticleCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [66]
Grabowska AD, Westermeier F, Nacul L et al.. “The importance of estimating prevalence of ME/CFS in future epidemiological studies of long COVID.” Frontiers in public health (2023). PMID: 38026427 ↗
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov'tCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [67]
Unger ER, Lin JS, Chen Y et al.. “Heterogeneity in Measures of Illness among Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Is Not Explained by Clinical Practice: A Study in Seven U.S. Specialty Clinics.” Journal of clinical medicine (2024). PMID: 38592199 ↗
Journal ArticleCited in: Clinical Phenotype: Post-Exertional Malaise and Multisystem Manifestations - [68]
Kujawski S, Tabisz H, Morten KJ et al.. “Diagnosis of chronic fatigue syndrome using beat-to-beat autonomic measurements.” Journal of translational medicine (2025). PMID: 41437251 ↗
Journal ArticleCited in: Clinical Diagnosis: History, Examination, and Application of Criteria - [69]
Milovanovic B, Markovic N, Petrovic M et al.. “Cross-Sectional Study Evaluating the Role of Autonomic Nervous System Functional Diagnostics in Differentiating Post-Infectious Syndromes: Post-COVID Syndrome, Chronic Fatigue Syndrome, and Lyme Disease.” Biomedicines (2025). PMID: 40002769 ↗
Journal ArticleCited in: Clinical Diagnosis: History, Examination, and Application of Criteria - [70]
Murovska M, Krumina A, Araja D et al.. “Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia - overlap, differences, and emerging insights.” Journal of translational medicine (2026). PMID: 41715182 ↗
Journal Article, Review, Research Support, Non-U.S. Gov'tCited in: Clinical Diagnosis: History, Examination, and Application of Criteria, Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [71]
Milovanovic B, Markovic N, Petrovic M et al.. “Assessment of Autonomic Nervous System Function in Patients with Chronic Fatigue Syndrome and Post-COVID-19 Syndrome Presenting with Recurrent Syncope.” Journal of clinical medicine (2025). PMID: 39941481 ↗
Journal ArticleCited in: Clinical Diagnosis: History, Examination, and Application of Criteria - [72]
Milovanovic B, Markovic N, Petrovic M et al.. “The Relationship Between Hemodynamic Responses During Head-Up Tilt Testing and Parameters of Infection in Post-COVID Syndrome, Chronic Fatigue Syndrome, and Late-Stage Lyme Disease.” Viruses (2025). PMID: 41305452 ↗
Journal ArticleCited in: Clinical Diagnosis: History, Examination, and Application of Criteria - [73]
van Campen CLMC, Rowe PC, Visser FC. “Two Different Hemodynamic Responses in ME/CFS Patients with Postural Orthostatic Tachycardia Syndrome During Head-Up Tilt Testing.” Journal of clinical medicine (2024). PMID: 39768649 ↗
Journal ArticleCited in: Clinical Diagnosis: History, Examination, and Application of Criteria - [74]
Miwa K. “Disequilibrium, Rather than Postural Orthostatic Tachycardia Syndrome, Is the Primary Determinant of Orthostatic Intolerance in Patients with Long COVID.” Journal of clinical medicine (2026). PMID: 41899187 ↗
Journal ArticleCited in: Clinical Diagnosis: History, Examination, and Application of Criteria, Severity, Functional Capacity, and Outcome Measurement - [75]
Miwa K. “Static and Kinetic Disequilibrium are Central Neural Signs in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Therapeutic Effect of Repetitive Transcranial Magnetic Stimulation.” Journal of integrative neuroscience (2025). PMID: 40302262 ↗
Clinical Trial, Journal ArticleCited in: Clinical Diagnosis: History, Examination, and Application of Criteria - [76]
Mihatsch L, Schartner L, de Luna JL et al.. “Handgrip strength in children, adolescents, and young adults with suspected myalgic encephalomyelitis/chronic fatigue syndrome.” Journal of translational medicine (2026). PMID: 42458481 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Clinical Diagnosis: History, Examination, and Application of Criteria, Severity, Functional Capacity, and Outcome Measurement, ME/CFS Across the Lifespan and in Special Clinical Contexts, Natural History, Prognosis, Follow-Up, and Research Priorities - [77]
Popkirov S. “Variation in Repeated Handgrip Strength Testing Indicates Submaximal Force Production in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” European journal of neurology (2025). PMID: 40923211 ↗
Journal ArticleCited in: Clinical Diagnosis: History, Examination, and Application of Criteria - [78]
Jones CL, Younger J. “Possible Racial Disparities in the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” International journal of environmental research and public health (2025). PMID: 40003505 ↗
Journal ArticleCited in: Clinical Diagnosis: History, Examination, and Application of Criteria - [79]
Tattan M, Hanssen DJC, Rosmalen JGM. “Who receives a diagnostic label for fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome? A study in the lifelines cohort.” Journal of psychosomatic research (2026). PMID: 41812541 ↗
Journal ArticleCited in: Clinical Diagnosis: History, Examination, and Application of Criteria - [80]
Bartholomew EJ, Medvedev ON, Petrie KJ et al.. “Rasch analysis of the hospital anxiety and depression scale in patients with chronic fatigue syndrome.” Journal of psychosomatic research (2025). PMID: 40939313 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Clinical Diagnosis: History, Examination, and Application of Criteria - [81]
Vernon SD, Zheng T, Do H et al.. “Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study.” Journal of general internal medicine (2025). PMID: 39804551 ↗
Journal Article, Observational Study, Research Support, N.I.H., ExtramuralCited in: Clinical Diagnosis: History, Examination, and Application of Criteria - [82]
Christopoulos EM, Tantanis D, Huang K et al.. “Mapping cerebral blood flow in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and orthostatic intolerance: insights from a systematic review.” Journal of translational medicine (2025). PMID: 40859389 ↗
Systematic Review, Journal Article, Research Support, Non-U.S. Gov'tCited in: Clinical Diagnosis: History, Examination, and Application of Criteria, Differential Diagnosis and Conditions That Commonly Coexist - [83]
Grach SL, Seltzer J, Chon TY et al.. “Diagnosis and Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Mayo Clinic proceedings (2023). PMID: 37793728 ↗
Journal Article, ReviewCited in: Investigations: Excluding Alternative Disease Without Overtesting - [84]
Steiner S, Fehrer A, Hoheisel F et al.. “Understanding, diagnosing, and treating Myalgic encephalomyelitis/chronic fatigue syndrome - State of the art: Report of the 2nd international meeting at the Charité Fatigue Center.” Autoimmunity reviews (2023). PMID: 37742748 ↗
Journal Article, ReviewCited in: Investigations: Excluding Alternative Disease Without Overtesting - [85]
Abrahamsen C, Beadsworth M, Bostock W et al.. “Persistent physical symptoms not explained by structural abnormalities or disease processes: a primary care approach to promote recovery.” Scandinavian journal of primary health care (2026). PMID: 41823400 ↗
Journal Article, ReviewCited in: Investigations: Excluding Alternative Disease Without Overtesting - [86]
Cheng AL, Herman E, Abramoff B et al.. “Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID: A compendium statement.” PM & R : the journal of injury, function, and rehabilitation (2025). PMID: 40261198 ↗
Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S.Cited in: Investigations: Excluding Alternative Disease Without Overtesting, Differential Diagnosis and Conditions That Commonly Coexist, Management Principles: Energy Management, Pacing, and Collaborative Care, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [87]
Ivanovska M, Homadi MS, Angelova G et al.. “Differential Characteristics and Comparison Between Long-COVID Syndrome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Biomedicines (2025). PMID: 41301889 ↗
Journal Article, ReviewCited in: Investigations: Excluding Alternative Disease Without Overtesting - [88]
Zingone F, Bai JC, Cellier C et al.. “Celiac Disease-Related Conditions: Who to Test?” Gastroenterology (2024). PMID: 38460606 ↗
Journal Article, ReviewCited in: Investigations: Excluding Alternative Disease Without Overtesting, Differential Diagnosis and Conditions That Commonly Coexist - [89]
Mohamed AZ, Andersen T, Radovic S et al.. “Objective sleep measures in chronic fatigue syndrome patients: A systematic review and meta-analysis.” Sleep medicine reviews (2023). PMID: 36948138 ↗
Meta-Analysis, Systematic Review, Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., ExtramuralCited in: Investigations: Excluding Alternative Disease Without Overtesting - [90]
Nakane S, Koike H, Hayashi T et al.. “Autoimmune Autonomic Neuropathy: From Pathogenesis to Diagnosis.” International journal of molecular sciences (2024). PMID: 38396973 ↗
Journal Article, ReviewCited in: Investigations: Excluding Alternative Disease Without Overtesting - [91]
Dooley M. “Biomarkers over Time: From Visual Contrast Sensitivity to Transcriptomics in Differentiating Chronic Inflammatory Response Syndrome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” International journal of molecular sciences (2025). PMID: 40806417 ↗
Journal Article, ReviewCited in: Investigations: Excluding Alternative Disease Without Overtesting - [92]
Taccori A, Maksoud R, Eaton-Fitch N et al.. “A systematic review and meta-analysis of urinary biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).” Journal of translational medicine (2023). PMID: 37408028 ↗
Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic ReviewCited in: Investigations: Excluding Alternative Disease Without Overtesting - [93]
Makhluf H, Madany H, Kim K. “Long COVID: Long-Term Impact of SARS-CoV2.” Diagnostics (Basel, Switzerland) (2024). PMID: 38611624 ↗
Journal Article, ReviewCited in: Investigations: Excluding Alternative Disease Without Overtesting - [94]
Komaroff AL, Lipkin WI. “ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature.” Frontiers in medicine (2023). PMID: 37342500 ↗
Journal Article, ReviewCited in: Investigations: Excluding Alternative Disease Without Overtesting - [95]
Latimer KM, Gunther A, Kopec M. “Fatigue in Adults: Evaluation and Management.” American family physician (2023). PMID: 37440739 ↗
Journal ArticleCited in: Differential Diagnosis and Conditions That Commonly Coexist - [96]
Fall EA, Chen Y, Lin JS et al.. “Chronic Overlapping Pain Conditions in people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a sample from the Multi-site Clinical Assessment of ME/CFS (MCAM) study.” BMC neurology (2024). PMID: 39425035 ↗
Journal Article, Multicenter StudyCited in: Differential Diagnosis and Conditions That Commonly Coexist - [97]
Giménez-Orenga K, Pierquin J, Brunel J et al.. “Blood parameters differentiate post COVID-19 condition from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia.” Brain, behavior, & immunity - health (2025). PMID: 40726775 ↗
Journal ArticleCited in: Differential Diagnosis and Conditions That Commonly Coexist - [98]
Huang K, G C de Sá A, Thomas N et al.. “Discriminating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and comorbid conditions using metabolomics in UK Biobank.” Communications medicine (2024). PMID: 39592839 ↗
Journal ArticleCited in: Differential Diagnosis and Conditions That Commonly Coexist - [99]
Novak P. “Head-down tilt reduces the heart rate in postural tachycardia syndrome in acute setting: a pilot study.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023). PMID: 37919442 ↗
Journal ArticleCited in: Differential Diagnosis and Conditions That Commonly Coexist - [100]
Tusconi M, Dursun SM, Pegreffi F et al.. “Bipolar spectrum, hypothyroidism, and their association with chronic fatigue/myalgic encephalomyelitis-like syndrome in long COVID: could they be identified as early determinants?” Frontiers in psychiatry (2025). PMID: 40950756 ↗
Journal ArticleCited in: Differential Diagnosis and Conditions That Commonly Coexist - [101]
Thomas NS, Neale MC, Kendler KS et al.. “Prospective associations between major depressive disorder, generalized anxiety disorder, fibromyalgia, and myalgic encephalomyelitis/chronic fatigue syndrome.” Psychological medicine (2025). PMID: 40785390 ↗
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., ExtramuralCited in: Differential Diagnosis and Conditions That Commonly Coexist - [102]
Coskun Benlidayi I, Ornek C, Deniz V et al.. “Reevaluating fibromyalgia diagnosis: a proposal to integrate deep tendon reflex responses into current criteria.” Rheumatology international (2025). PMID: 40172661 ↗
Journal Article, Review, Research Support, Non-U.S. Gov'tCited in: Differential Diagnosis and Conditions That Commonly Coexist - [103]
Xie F, You Y, Ma J et al.. “Associated factors and assessment of clinical symptoms including fatigue, insomnia, and gastrointestinal discomfort of chronic fatigue syndrome: a cross-sectional case-control study.” Journal of translational medicine (2026). PMID: 41654906 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Differential Diagnosis and Conditions That Commonly Coexist - [104]
Grach SL, Dudenkov DV, Pollack B et al.. “Overlapping conditions in Long COVID at a multisite academic center.” Frontiers in neurology (2024). PMID: 39524912 ↗
Journal ArticleCited in: Differential Diagnosis and Conditions That Commonly Coexist - [105]
Peo LC, Wiehler K, Paulick J et al.. “Pediatric and adult patients with ME/CFS following COVID-19: A structured approach to diagnosis using the Munich Berlin Symptom Questionnaire (MBSQ).” European journal of pediatrics (2023). PMID: 38095713 ↗
Journal ArticleCited in: Differential Diagnosis and Conditions That Commonly Coexist, Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [106]
Eguchi A, Kuratsune H, Nakatomi Y et al.. “Circulating extracellular vesicles-microRNAs as potential biomarkers for the identification of ME/CFS: differentiating fatigue-related conditions.” Journal of translational medicine (2026). PMID: 42533331 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Differential Diagnosis and Conditions That Commonly Coexist - [107]
Thomas NS, Gillespie NA, Neale MC et al.. “Clinical heterogeneity in major depressive disorder underlies comorbidity with functional disorders.” Journal of psychiatric research (2025). PMID: 39923353 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Differential Diagnosis and Conditions That Commonly Coexist - [108]
Saini U, Aggen SH, Oldehinkel AJ et al.. “Disentangling comorbidity: symptom dimensions of internalizing and functional disorders in a large general population sample.” BMC psychiatry (2026). PMID: 41546021 ↗
Journal ArticleCited in: Differential Diagnosis and Conditions That Commonly Coexist - [109]
Peebles KC, Jacobs C, Makaroff L et al.. “The use and effectiveness of exercise for managing postural orthostatic tachycardia syndrome in young adults with joint hypermobility and related conditions: A scoping review.” Autonomic neuroscience : basic & clinical (2024). PMID: 38401460 ↗
Case Reports, Journal Article, Scoping ReviewCited in: Differential Diagnosis and Conditions That Commonly Coexist - [110]
Fricke C, Deibert P, Maier P et al.. “ACHTSAM study protocol: outreach diagnostics and assessment of tolerability in severe ME/CFS-a pilot study.” BMJ open (2026). PMID: 41791789 ↗
Journal Article, Observational StudyCited in: Severity, Functional Capacity, and Outcome Measurement, Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [111]
Eaton-Fitch N, Marshall-Gradisnik S. “Australian registry reports poor health and wellbeing in people living with ME/CFS.” Journal of translational medicine (2026). PMID: 42443918 ↗
Journal ArticleCited in: Severity, Functional Capacity, and Outcome Measurement - [112]
Welch DC, Edwards CC, Broussard CA et al.. “Validation of the Wood Mental Fatigue Inventory in adolescents with myalgic encephalomyelitis/chronic fatigue syndrome.” Brain, behavior, & immunity - health (2026). PMID: 41953581 ↗
Journal ArticleCited in: Severity, Functional Capacity, and Outcome Measurement, ME/CFS Across the Lifespan and in Special Clinical Contexts - [113]
Jason LA, Furst J, Worth R et al.. “Outcomes of ME/CFS following infectious mononucleosis: seven-year follow-up of a prospective study.” Frontiers in medicine (2026). PMID: 41836950 ↗
Journal ArticleCited in: Severity, Functional Capacity, and Outcome Measurement - [114]
Kim L, Cammà G, Peters CK et al.. “Hyperbaric oxygen therapy improves clinical symptoms and functional capacity and modulates thalamic connectivity in ME/CFS: a prospective cohort study.” Journal of translational medicine (2026). PMID: 42249466 ↗
Journal Article, Observational Study, Research Support, Non-U.S. Gov'tCited in: Severity, Functional Capacity, and Outcome Measurement - [115]
Zhao L, Gou B, Zhang M. “The efficacy of exercise in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review and meta-analysis.” Journal of psychosomatic research (2026). PMID: 42000527 ↗
Journal Article, Systematic Review, Meta-Analysis, Research Support, Non-U.S. Gov'tCited in: Severity, Functional Capacity, and Outcome Measurement - [116]
Gao J, Liu Y, Wang S et al.. “Exercise interventions for physical function, psychological health, and quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia: A systematic review and network meta-analysis.” Journal of psychosomatic research (2026). PMID: 41861756 ↗
Journal Article, Systematic Review, Network Meta-Analysis, Research Support, Non-U.S. Gov'tCited in: Severity, Functional Capacity, and Outcome Measurement - [117]
Schmidt L, Feddern S, Kossow A et al.. “Severe acute COVID-19 and early long COVID signals in paediatric cohorts: an analysis of real-world data from two health departments, Germany.” BMC pediatrics (2026). PMID: 41840550 ↗
Journal ArticleCited in: Severity, Functional Capacity, and Outcome Measurement - [118]
Habermann-Horstmeier L, Horstmeier LM. “Symptom clusters in ME/CFS reflect distinct neuroimmune and autonomic pathophysiological mechanisms: a translational model.” Journal of translational medicine (2026). PMID: 42050709 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Severity, Functional Capacity, and Outcome Measurement - [119]
Grønning K, Lysfjord LE, Røstad AKH. “Self-management support needs for individuals with Myalgic Encephalomyelitis and their next of kin - a qualitative study.” BMC health services research (2026). PMID: 42298601 ↗
Journal ArticleCited in: Severity, Functional Capacity, and Outcome Measurement, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity, ME/CFS Across the Lifespan and in Special Clinical Contexts - [120]
Goudsmit EM, Nijs J, Jason LA et al.. “Pacing as a strategy to improve energy management in myalgic encephalomyelitis/chronic fatigue syndrome: a consensus document.” Disability and rehabilitation (2011). PMID: 22181560 ↗
Journal Article, Review, Consensus StatementCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [121]
Kingdon C, Lowe A, Shepherd C et al.. “What Primary Care Practitioners Need to Know about the New NICE Guideline for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults.” Healthcare (Basel, Switzerland) (2022). PMID: 36553962 ↗
Journal ArticleCited in: Management Principles: Energy Management, Pacing, and Collaborative Care, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [122]
Thornton EJ, Hayes LD, Goodwin DS et al.. “Managing Energy, and Shaping Care: Insights from Adults with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Through Co-Production Workshops.” The American journal of medicine (2025). PMID: 39961545 ↗
Journal ArticleCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [123]
Ribeiro V, Azevedo P, Westermeier F et al.. “A Short-Term Pacing Intervention in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study in Portugal.” Medicina (Kaunas, Lithuania) (2026). PMID: 41752730 ↗
Journal ArticleCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [124]
Pinxsterhuis I, Nordstokkå K, Jakobsen FA. “Theoretical foundation of the Activity Calculator - a method for fatigue management.” Scandinavian journal of occupational therapy (2025). PMID: 41474036 ↗
Journal ArticleCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [125]
White P, Abbey S, Angus B et al.. “Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis.” Journal of neurology, neurosurgery, and psychiatry (2023). PMID: 37434321 ↗
Journal Article, ReviewCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [126]
Vink M, Vink-Niese A. “The Updated NICE Guidance Exposed the Serious Flaws in CBT and Graded Exercise Therapy Trials for ME/CFS.” Healthcare (Basel, Switzerland) (2022). PMID: 35628033 ↗
Journal Article, ReviewCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [127]
Brown SI. “Graded exercise therapy for ME/CFS: finding consensus between the royal colleges, patients, and researchers.” BMJ (Clinical research ed.) (2021). PMID: 34880053 ↗
LetterCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [128]
Barr J, Marsden L, Dassanayake T et al.. “Testing a Personalised Dysautonomia Management Protocol in Patients with Orthostatic Intolerance and a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome or Long COVID.” Journal of clinical medicine (2026). PMID: 41976810 ↗
Journal ArticleCited in: Management Principles: Energy Management, Pacing, and Collaborative Care, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity, ME/CFS Across the Lifespan and in Special Clinical Contexts - [129]
Schiweck N, Langer K, Maier A et al.. “Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS).” Clinical autonomic research : official journal of the Clinical Autonomic Research Society (2025). PMID: 41225175 ↗
Journal Article, Systematic ReviewCited in: Management Principles: Energy Management, Pacing, and Collaborative Care, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [130]
Haghshenas M, Steinsbekk A, Landmark T et al.. “Information exchange or discussion? A qualitative study on cross-sectoral collaboration between social security service and healthcare service for patients with chronic fatigue.” BMC health services research (2025). PMID: 41366432 ↗
Journal ArticleCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [131]
Rowe PC, Underhill RA, Friedman KJ et al.. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer.” Frontiers in pediatrics (2017). PMID: 28674681 ↗
Journal Article, ReviewCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [132]
Royston AP, Burge S, Idini I et al.. “Management of severe ME/CFS in children and young people in the UK: a British Paediatric Surveillance Unit study.” BMJ paediatrics open (2024). PMID: 38453418 ↗
Journal ArticleCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [133]
Weigel B, Eaton-Fitch N, Passmore R et al.. “A preliminary investigation of nutritional intake and supplement use in Australians with myalgic encephalomyelitis/chronic fatigue syndrome and the implications on health-related quality of life.” Food & nutrition research (2021). PMID: 34262415 ↗
Journal ArticleCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [134]
Balke M, Garbsch R, Cormann J et al.. “Design and validation of an energy level diary for fatigue management in patients with post-COVID syndrome.” Frontiers in rehabilitation sciences (2025). PMID: 40761505 ↗
Journal ArticleCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [135]
Abdulla AD, Sas C, Doherty G. “Functionality Review of Mobile Apps for the Tracking and Self-Management of Fatigue: Systematic Search in App Stores and Content Analysis.” JMIR mHealth and uHealth (2026). PMID: 42579879 ↗
Journal ArticleCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [136]
Mallet M, King E, White PD. “A UK based review of recommendations regarding the management of chronic fatigue syndrome.” Journal of psychosomatic research (2016). PMID: 27521650 ↗
Comparative Study, Journal ArticleCited in: Management Principles: Energy Management, Pacing, and Collaborative Care - [137]
Bateman L, Bested AC, Bonilla HF et al.. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management.” Mayo Clinic proceedings (2021). PMID: 34454716 ↗
Journal Article, ReviewCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [138]
Nacul L, Authier FJ, Scheibenbogen C et al.. “European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe.” Medicina (Kaunas, Lithuania) (2021). PMID: 34069603 ↗
Journal Article, Consensus StatementCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [139]
Montoya JG, Dowell TG, Mooney AE et al.. “Caring for the Patient with Severe or Very Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Healthcare (Basel, Switzerland) (2021). PMID: 34683011 ↗
Journal ArticleCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [140]
Dorczok MC, Mossaheb N, Mittmann G et al.. “Use and Perceived Helpfulness of Different Intervention Strategies in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Depression.” Journal of clinical medicine (2026). PMID: 41598786 ↗
Journal ArticleCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [141]
Grande T, Grande B, Gerner P et al.. “The Role of Psychotherapy in the Care of Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Medicina (Kaunas, Lithuania) (2023). PMID: 37109676 ↗
Journal ArticleCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [142]
Deumer US, Varesi A, Floris V et al.. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview.” Journal of clinical medicine (2021). PMID: 34682909 ↗
Journal Article, ReviewCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [143]
d'Incau E, Kaplan CM, Micoulaud-Franchi JA et al.. “Multimorbidity in Chronic Overlapping Pain Conditions: From Burden to Integrated Care.” Journal of clinical medicine (2026). PMID: 42356003 ↗
Journal Article, ReviewCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity, ME/CFS Across the Lifespan and in Special Clinical Contexts - [144]
Agarwal P, Friedman KJ. “Reframing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Biological Basis of Disease and Recommendations for Supporting Patients.” Healthcare (Basel, Switzerland) (2025). PMID: 40805949 ↗
Journal ArticleCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [145]
Sun H, Dang R, Li P et al.. “Facility-measured sleep electroencephalographic microstructures in long COVID.” Sleep (2026). PMID: 42017829 ↗
Journal ArticleCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [146]
Seton KA, Espejo-Oltra JA, Giménez-Orenga K et al.. “Advancing Research and Treatment: An Overview of Clinical Trials in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Future Perspectives.” Journal of clinical medicine (2024). PMID: 38256459 ↗
Journal Article, ReviewCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbidity - [147]
Vink M, Vink-Niese A. “An Overview of Severe Myalgic Encephalomyelitis.” Journal of clinical medicine (2026). PMID: 41598742 ↗
Journal Article, ReviewCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [148]
Reuken PA, Besteher B, Bleidorn J et al.. “Web-based telemedicine approach for treatment of post-COVID-19 in Thuringia (WATCH).” Digital health (2024). PMID: 39493638 ↗
Journal ArticleCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [149]
Colgan DD, Stadler DD, Grow T et al.. “Telehealth-Based Ketogenic Metabolic Therapy With Lifestyle Interventions for Post-viral Illness: A Research Brief of Patients' Experiences.” Journal of patient experience (2026). PMID: 42416120 ↗
Journal ArticleCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [150]
Verduzco-Gutierrez M, Fleming TK, Azola AM. “Considerations for Long COVID Rehabilitation in Women.” Physical medicine and rehabilitation clinics of North America (2024). PMID: 40210368 ↗
Journal Article, ReviewCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [151]
Takamatsu N, Kuga H. “Applicability and adaptation of cognitive behavior therapy for long COVID neuropsychiatric symptoms: a review with insights from ME/CFS.” BMC infectious diseases (2025). PMID: 41073921 ↗
Journal Article, ReviewCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [152]
Vester P, Boudouroglou-Walter S, Schreyögg J et al.. “Burden of Disease in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Scoping Review.” Applied health economics and health policy (2025). PMID: 40986167 ↗
Journal Article, Scoping ReviewCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [153]
Paffrath A, Kim L, Kedor C et al.. “Impaired Hand Grip Strength Correlates with Greater Disability and Symptom Severity in Post-COVID Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of clinical medicine (2024). PMID: 38610918 ↗
Journal ArticleCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [154]
Stallmach A, Quickert S, Puta C et al.. “The gastrointestinal microbiota in the development of ME/CFS: a critical view and potential perspectives.” Frontiers in immunology (2024). PMID: 38605969 ↗
Journal Article, ReviewCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [155]
Cherneva R, Cherneva Z, Youroukova V et al.. “Autonomic Dysfunction and Low Cardio-Respiratory Fitness in Long-Term Post-COVID-19 Syndrome.” Biomedicines (2025). PMID: 40426965 ↗
Journal ArticleCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [156]
Scheibenbogen C, Wirth KJ. “Key Pathophysiological Role of Skeletal Muscle Disturbance in Post COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Accumulated Evidence.” Journal of cachexia, sarcopenia and muscle (2025). PMID: 39727052 ↗
Journal Article, Review, Research Support, Non-U.S. Gov'tCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [157]
Serrat M, Navarrete J, Ferrés S et al.. “Effectiveness of an online multicomponent program (FATIGUEWALK) for chronic fatigue syndrome: A randomized controlled trial.” Health psychology : official journal of the Division of Health Psychology, American Psychological Association (2023). PMID: 38127508 ↗
Randomized Controlled Trial, Journal ArticleCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [158]
Wirth KJ, Steinacker JM. “The potential causes of myasthenia and fasciculations in severely ill ME/CFS patients: the role of disturbed electrophysiology.” Frontiers in physiology (2026). PMID: 41705124 ↗
Journal ArticleCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [159]
Hyland ME, Antonacci Y, Bacon AM. “Comparison of the symptom networks of long-COVID and chronic fatigue syndrome: From modularity to connectionism.” Scandinavian journal of psychology (2024). PMID: 39034480 ↗
Journal Article, Comparative StudyCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [160]
Huff HV, Roberts H, Bartrum E et al.. “Prevalence and severity of neurologic symptoms in Long-COVID and the role of pre-existing conditions, hospitalization, and mental health.” Frontiers in neurology (2025). PMID: 40635708 ↗
Journal ArticleCited in: Severe and Very Severe ME/CFS: Home-Based Care and Medical Complications - [161]
Yuan Y, Wen L, Fu H et al.. “Distribution characteristics of chronic fatigue syndrome among secondary school students and its association with physical health: a case study in Shaanxi Province.” Frontiers in pediatrics (2026). PMID: 42519734 ↗
Journal ArticleCited in: ME/CFS Across the Lifespan and in Special Clinical Contexts - [162]
Weidmann C, Grabbe A, Eberhartinger M et al.. “Novel activity and participation scales for children, adolescents, and young adults with postacute infection and vaccination syndromes and/or ME/CFS.” European journal of pediatrics (2026). PMID: 42249231 ↗
Journal Article, Validation StudyCited in: ME/CFS Across the Lifespan and in Special Clinical Contexts - [163]
Donath Q, Haegele M, Schindler D et al.. “Risk factors for severe post-COVID condition in children, adolescents, and young adults.” European journal of pediatrics (2026). PMID: 42082813 ↗
Journal Article, Observational StudyCited in: ME/CFS Across the Lifespan and in Special Clinical Contexts - [164]
Sanal-Hayes NEM, Hayes LD, Mclaughlin M et al.. “Pacing and energy management with digital tools for conditions with chronic fatigue: What we know so far in ME/CFS and Long COVID.” PLOS digital health (2026). PMID: 42507687 ↗
Journal ArticleCited in: ME/CFS Across the Lifespan and in Special Clinical Contexts - [165]
Plaut S. “A systematic scoping review and conceptual analysis of new-onset fibromyalgia manifestations after non-hospitalized COVID-19: empirics, definitions, methodologies, pathophysiology, mapping of literature, and knowledge gaps.” Journal of translational medicine (2026). PMID: 42174645 ↗
Journal Article, Scoping ReviewCited in: ME/CFS Across the Lifespan and in Special Clinical Contexts - [166]
Saini U, Wanders R, Oldehinkel AJ et al.. “Data-driven subtypes of internalizing and functional somatic symptoms: A hybrid mixture modeling approach.” General hospital psychiatry (2026). PMID: 42594760 ↗
Journal ArticleCited in: ME/CFS Across the Lifespan and in Special Clinical Contexts, Natural History, Prognosis, Follow-Up, and Research Priorities - [167]
Herrero Babiloni A, Brown C, Ash P et al.. “A Description of Health Care Utilization in Young Adults With Chronic Overlapping Pain.” The Clinical journal of pain (2026). PMID: 41919472 ↗
Journal ArticleCited in: ME/CFS Across the Lifespan and in Special Clinical Contexts - [168]
Dooms Y, Qiu L, Coppieters I et al.. “Multimodal approach to identify neuropsychophysiological subgroups in myalgic encephalomyelitis/chronic fatigue syndrome and their relevance for rehabilitation: protocol for a mechanistic cross-sectional and longitudinal study.” Brain, behavior, & immunity - health (2026). PMID: 42472232 ↗
Journal ArticleCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [169]
Mao S, Wu L. “The role of disease history score in the association between depression history and current ME/CFS among US adults.” Frontiers in public health (2026). PMID: 42553043 ↗
Journal ArticleCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [170]
Walter S. “ME/CFS and the emotional toll of persistent disbelief: from epistemic to affective injustice.” Medicine, health care, and philosophy (2026). PMID: 42599643 ↗
Journal ArticleCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [171]
Westermeier F, Pretorius E, Untersmayr E et al.. “A cardiometabolic perspective on post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.” Cardiovascular diabetology (2026). PMID: 42625219 ↗
EditorialCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [172]
Nochi M, Kristensen SK, Mehrani N et al.. “REenergizeME: intermittent hypoxia-hyperoxia treatment for myalgic encephalomyelitis/chronic fatigue syndrome-protocol for a randomised, placebo-controlled trial.” BMJ open (2026). PMID: 42601095 ↗
Journal Article, Clinical Trial ProtocolCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [173]
Rusin A, Cocchetto A, Mothersill C. “Low-Dose Ionizing Radiation and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Review of Recent Evidence and Future Research Directions Toward the Elucidation of a Metabolic, Immunologic, and Signaling Cascade.” International journal of molecular sciences (2026). PMID: 42511874 ↗
Journal Article, ReviewCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [174]
Wendt K, Schieck M, Gille C et al.. “Biomarkers of post-acute infection syndrome: a systematic literature review.” Frontiers in immunology (2026). PMID: 42454043 ↗
Journal Article, Systematic ReviewCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [175]
Hunter E, Alshaker H, Vugrinec D et al.. “Beyond genes: EpiSwitch® and Orion platform-powered 3D genome architecture biomarkers reveal shared biology across ME/CFS, long COVID, PTSD, rheumatoid arthritis, and multiple sclerosis.” Journal of translational medicine (2026). PMID: 42693463 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [176]
Moezzi A, Elremaly W, Leveau C et al.. “Haptoglobin Phenotypes Stratify Post-Exertional Cognitive Dysfunction Associated with Altered Cerebral Oxygenation and Metabolic Signatures in Long COVID.” International journal of molecular sciences (2026). PMID: 42589652 ↗
Journal Article, Observational StudyCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [177]
Rajabi N, Ramdass PVAK. “Association between myalgic encephalomyelitis/chronic fatigue syndrome and irritable bowel syndrome: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42577233 ↗
Journal Article, Systematic ReviewCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [178]
Amoroso C, Marinoni B, Maragno P et al.. “VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial.” British journal of biomedical science (2026). PMID: 42577968 ↗
Journal Article, Randomized Controlled TrialCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [179]
Hu Q, Qi B, Liu Y et al.. “Clinical efficacy of Jianqiao ancient moxibustion in treating chronic fatigue syndrome: a single-center randomized controlled superiority trial protocol.” Frontiers in medicine (2026). PMID: 42434010 ↗
Journal ArticleCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [180]
Jamrasi P, Seo JW, Sung Y et al.. “Efficacy and Safety of Enzyme-Derived Deer Velvet Extract Supplementation on Adults with Chronic Fatigue: a Randomized, Placebo-Controlled, Double-Blind Trial.” Journal of microbiology and biotechnology (2026). PMID: 42487402 ↗
Journal Article, Randomized Controlled TrialCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [181]
Wu Y, Wen X, Fang Z et al.. “Cognitive impairment and prefrontal TGF-β1 elevation in a rat model of fatigue.” Frontiers in psychiatry (2026). PMID: 42404713 ↗
Journal ArticleCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [182]
Holmes-McCoid HJ, Lecky FE. “Exploring the influence of long COVID upon self-identity: a systematic literature review.” Archives of public health = Archives belges de sante publique (2026). PMID: 42638142 ↗
Journal Article, Systematic ReviewCited in: Natural History, Prognosis, Follow-Up, and Research Priorities - [183]
Leonardi G, Bonanno F, Alito A et al.. “More than Rehabilitation: The Role of Contextual Factors in Pain Perception and Recovery: What the Physiotherapy Literature Reports-A Narrative Review with a Systematic Search Strategy.” Journal of clinical medicine (2026). PMID: 42652892 ↗
Journal Article, ReviewCited in: Natural History, Prognosis, Follow-Up, and Research Priorities